Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess whether a proactive therapeutic drug monitoring
strategy, introduced early during treatment, improves Infliximab (IFX) durability, efficacy
and safety in children and young adults with inflammatory bowel disease. Patients with an
indication to receive IFX, based on current clinical practice recommendations, will receive
the drug either based on IFX concentrations determined before every IFX infusion, starting
from the third infusion, or at standard dosing. Approximately 90 patients will be included in
this research study. Patients enrolled will be in the study for approximately 12 months.